Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05740293 · ClinicalTrials.gov registry record
Post-approval Study of New Enrolment Patients Undergoing Bilateral Treatment With the VisuMax SMILE Procedure
A clinical trial, sponsored by Carl Zeiss Meditec.
- Completed
- Registry status
- 186
- Enrollment target
NCT05740293 is a clinical trial that has completed, run by Carl Zeiss Meditec. The registered enrollment target is 186 participants.
The verdict
NCT05740293 has completed, sponsored by Carl Zeiss Meditec.
- COMPLETED
- Registry status
- 186 participants
- Enrollment target
Study Summary
The objective of the post-approval study (PAS) is to assess patient experience of visual symptoms 6 months after bilateral treatment with the VisuMax SMILE procedure as measured by a patient questionnaire.
Interventions
- PROCEDURE VisuMax SMILE procedure for the reduction or elimination of myopia with astigmatism
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 186 participants |
| Start Date | 2022-04-05 |
| Est. Completion | 2025-08-25 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05740293
The ClinicalTrials.gov registry entry for NCT05740293 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 186 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Carl Zeiss Meditec, which has 18 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which VisuMax SMILE procedure for the reduction or elimination of myopia with astigmatism is the first listed.
NCT05740293 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05740293 about?
NCT05740293 is a clinical study titled "Post-approval Study of New Enrolment Patients Undergoing Bilateral Treatment With the VisuMax SMILE Procedure". The objective of the post-approval study (PAS) is to assess patient experience of visual symptoms 6 months after bilateral treatment with the VisuMax SMILE procedure as measured by a patient questionnaire.
What is the current status of trial NCT05740293?
This trial is currently completed. The enrollment target is 186 participants. The study started on 2022-04-05. Estimated completion is 2025-08-25.
What interventions are being tested in trial NCT05740293?
The interventions under investigation include: VisuMax SMILE procedure for the reduction or elimination of myopia with astigmatism (PROCEDURE).
Who is sponsoring clinical trial NCT05740293?
This trial is sponsored by Carl Zeiss Meditec, which has 18 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.